nasdaq:acrx
|
138596
|
Apr 14th, 2024 12:00AM
|
Talphera, Inc.
|
3.5K
|
39.00
|
Open
|
|
Apr 13th, 2024 10:29PM
|
Apr 14th, 2024 10:29AM
|
Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. Talphera’s lead product candidate, Niyad is a lyophilized formulation of nafamostat and is currently being studied under an investigational device exemption, or IDE, as an anticoagulant for the extracorporeal circuit, and has received Breakthrough Device Designation Status from the FDA. Talphera is also developing two pre-filled syringes in-licensed from its partner Aguettant: Fedsyra™, a pre-filled ephedrine syringe, and PFS-02, a pre-filled phenylephrine syringe.
To learn more about the development status of these product candidates, please visit our website at www.talphera.com.
|
Open
|
pharmaceuticals, research & development, and pain management
|
Open
|
1850 Gateway Dr
|
San Mateo
|
California
|
US
|
94404
|
|
AcelRx Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:acrx
|
138596
|
Apr 13th, 2024 12:00AM
|
Talphera, Inc.
|
3.5K
|
39.00
|
Open
|
|
Apr 12th, 2024 10:20PM
|
Apr 13th, 2024 10:57AM
|
Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. Talphera’s lead product candidate, Niyad is a lyophilized formulation of nafamostat and is currently being studied under an investigational device exemption, or IDE, as an anticoagulant for the extracorporeal circuit, and has received Breakthrough Device Designation Status from the FDA. Talphera is also developing two pre-filled syringes in-licensed from its partner Aguettant: Fedsyra™, a pre-filled ephedrine syringe, and PFS-02, a pre-filled phenylephrine syringe.
To learn more about the development status of these product candidates, please visit our website at www.talphera.com.
|
Open
|
pharmaceuticals, research & development, and pain management
|
Open
|
1850 Gateway Dr
|
San Mateo
|
California
|
US
|
94404
|
|
AcelRx Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:acrx
|
138596
|
Apr 12th, 2024 12:00AM
|
Talphera, Inc.
|
3.5K
|
39.00
|
Open
|
|
Apr 11th, 2024 10:23PM
|
Apr 12th, 2024 07:52AM
|
Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. Talphera’s lead product candidate, Niyad is a lyophilized formulation of nafamostat and is currently being studied under an investigational device exemption, or IDE, as an anticoagulant for the extracorporeal circuit, and has received Breakthrough Device Designation Status from the FDA. Talphera is also developing two pre-filled syringes in-licensed from its partner Aguettant: Fedsyra™, a pre-filled ephedrine syringe, and PFS-02, a pre-filled phenylephrine syringe.
To learn more about the development status of these product candidates, please visit our website at www.talphera.com.
|
Open
|
pharmaceuticals, research & development, and pain management
|
Open
|
1850 Gateway Dr
|
San Mateo
|
California
|
US
|
94404
|
|
AcelRx Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:acrx
|
138596
|
Apr 11th, 2024 12:00AM
|
Talphera, Inc.
|
3.5K
|
39.00
|
Open
|
|
Apr 10th, 2024 10:41PM
|
Apr 11th, 2024 10:36AM
|
Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. Talphera’s lead product candidate, Niyad is a lyophilized formulation of nafamostat and is currently being studied under an investigational device exemption, or IDE, as an anticoagulant for the extracorporeal circuit, and has received Breakthrough Device Designation Status from the FDA. Talphera is also developing two pre-filled syringes in-licensed from its partner Aguettant: Fedsyra™, a pre-filled ephedrine syringe, and PFS-02, a pre-filled phenylephrine syringe.
To learn more about the development status of these product candidates, please visit our website at www.talphera.com.
|
Open
|
pharmaceuticals, research & development, and pain management
|
Open
|
1850 Gateway Dr
|
San Mateo
|
California
|
US
|
94404
|
|
AcelRx Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:acrx
|
138596
|
Apr 10th, 2024 12:00AM
|
Talphera, Inc.
|
3.5K
|
39.00
|
Open
|
|
Apr 9th, 2024 10:27PM
|
Apr 10th, 2024 04:45PM
|
Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. Talphera’s lead product candidate, Niyad is a lyophilized formulation of nafamostat and is currently being studied under an investigational device exemption, or IDE, as an anticoagulant for the extracorporeal circuit, and has received Breakthrough Device Designation Status from the FDA. Talphera is also developing two pre-filled syringes in-licensed from its partner Aguettant: Fedsyra™, a pre-filled ephedrine syringe, and PFS-02, a pre-filled phenylephrine syringe.
To learn more about the development status of these product candidates, please visit our website at www.talphera.com.
|
Open
|
pharmaceuticals, research & development, and pain management
|
Open
|
1850 Gateway Dr
|
San Mateo
|
California
|
US
|
94404
|
|
AcelRx Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:acrx
|
138596
|
Apr 9th, 2024 12:00AM
|
Talphera, Inc.
|
3.5K
|
39.00
|
Open
|
|
Apr 8th, 2024 10:37PM
|
Apr 9th, 2024 09:26AM
|
Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. Talphera’s lead product candidate, Niyad is a lyophilized formulation of nafamostat and is currently being studied under an investigational device exemption, or IDE, as an anticoagulant for the extracorporeal circuit, and has received Breakthrough Device Designation Status from the FDA. Talphera is also developing two pre-filled syringes in-licensed from its partner Aguettant: Fedsyra™, a pre-filled ephedrine syringe, and PFS-02, a pre-filled phenylephrine syringe.
To learn more about the development status of these product candidates, please visit our website at www.talphera.com.
|
Open
|
pharmaceuticals, research & development, and pain management
|
Open
|
1850 Gateway Dr
|
San Mateo
|
California
|
US
|
94404
|
|
AcelRx Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:acrx
|
138596
|
Apr 8th, 2024 12:00AM
|
Talphera, Inc.
|
3.5K
|
39.00
|
Open
|
|
Apr 7th, 2024 10:45PM
|
Apr 8th, 2024 06:24PM
|
Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. Talphera’s lead product candidate, Niyad is a lyophilized formulation of nafamostat and is currently being studied under an investigational device exemption, or IDE, as an anticoagulant for the extracorporeal circuit, and has received Breakthrough Device Designation Status from the FDA. Talphera is also developing two pre-filled syringes in-licensed from its partner Aguettant: Fedsyra™, a pre-filled ephedrine syringe, and PFS-02, a pre-filled phenylephrine syringe.
To learn more about the development status of these product candidates, please visit our website at www.talphera.com.
|
Open
|
pharmaceuticals, research & development, and pain management
|
Open
|
1850 Gateway Dr
|
San Mateo
|
California
|
US
|
94404
|
|
AcelRx Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:acrx
|
138596
|
Apr 7th, 2024 12:00AM
|
Talphera, Inc.
|
3.5K
|
39.00
|
Open
|
|
Apr 6th, 2024 10:36PM
|
Apr 6th, 2024 10:36PM
|
Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. Talphera’s lead product candidate, Niyad is a lyophilized formulation of nafamostat and is currently being studied under an investigational device exemption, or IDE, as an anticoagulant for the extracorporeal circuit, and has received Breakthrough Device Designation Status from the FDA. Talphera is also developing two pre-filled syringes in-licensed from its partner Aguettant: Fedsyra™, a pre-filled ephedrine syringe, and PFS-02, a pre-filled phenylephrine syringe.
To learn more about the development status of these product candidates, please visit our website at www.talphera.com.
|
Open
|
pharmaceuticals, research & development, and pain management
|
Open
|
1850 Gateway Dr
|
San Mateo
|
California
|
US
|
94404
|
|
AcelRx Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:acrx
|
138596
|
Apr 6th, 2024 12:00AM
|
Talphera, Inc.
|
3.5K
|
39.00
|
Open
|
|
Apr 5th, 2024 10:35PM
|
Apr 5th, 2024 10:35PM
|
Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. Talphera’s lead product candidate, Niyad is a lyophilized formulation of nafamostat and is currently being studied under an investigational device exemption, or IDE, as an anticoagulant for the extracorporeal circuit, and has received Breakthrough Device Designation Status from the FDA. Talphera is also developing two pre-filled syringes in-licensed from its partner Aguettant: Fedsyra™, a pre-filled ephedrine syringe, and PFS-02, a pre-filled phenylephrine syringe.
To learn more about the development status of these product candidates, please visit our website at www.talphera.com.
|
Open
|
pharmaceuticals, research & development, and pain management
|
Open
|
1850 Gateway Dr
|
San Mateo
|
California
|
US
|
94404
|
|
AcelRx Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:acrx
|
138596
|
Apr 5th, 2024 12:00AM
|
Talphera, Inc.
|
3.5K
|
39.00
|
Open
|
|
Apr 4th, 2024 10:41PM
|
Apr 4th, 2024 10:41PM
|
Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. Talphera’s lead product candidate, Niyad is a lyophilized formulation of nafamostat and is currently being studied under an investigational device exemption, or IDE, as an anticoagulant for the extracorporeal circuit, and has received Breakthrough Device Designation Status from the FDA. Talphera is also developing two pre-filled syringes in-licensed from its partner Aguettant: Fedsyra™, a pre-filled ephedrine syringe, and PFS-02, a pre-filled phenylephrine syringe.
To learn more about the development status of these product candidates, please visit our website at www.talphera.com.
|
Open
|
pharmaceuticals, research & development, and pain management
|
Open
|
1850 Gateway Dr
|
San Mateo
|
California
|
US
|
94404
|
|
AcelRx Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|